cyclo(argglyaspdpheval) tfa

Cyclo(RLsKDK) (TFA) (BK-1361 (TFA)) is a specific inhibitor of the metalloproteinase ADAM8, demonstrating an IC50 value of 182 nM. It has shown potential for application in the treatment of inflammatory diseases and cancer [1].

Arg-Gly-Asp-D-Phe-Val (TFA) has anti-tumor activity and is an inhibitor of integrin αvβ3.

Cyclo(-RGDfK) is a selective αvβ3 integrin inhibitor(IC50 : 0.94 nM).

TAT-cyclo-CLLFVY TFA is a cyclic peptide inhibitor specifically targeting HIF-1 heterodimerization to mitigate hypoxia signaling within cancer cells. It effectively disrupts the protein-protein interaction between HIF-1α and HIF-1β, demonstrating an inhibitory concentration (IC 50) of 1.3 μM [1].

Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA (Cyclo RGDfC) TFA, a cyclic RGD peptide, displays a high affinity for αvβ3 integrin, effectively disrupting cell-integrin interactions. It suppresses pluripotent marker expression in embryonic stem cells (ESCs) and reduces the tumorigenic capability of mESCs in vivo, making it valuable in tumor research [1].

SYNV-cyclo(CGGYF) TFA, a C5 autoinducing peptide derived from Staphylococcus hominis (S. hominis), demonstrates inhibition of S. aureus activity, holding potential for research into S. aureus-mediated epithelial damage and inflammation [1].

Cyclo(his-pro) is an endogenous cyclic dipeptide that exerts oxidative damage protection by selectively activating the transcription factor Nrf2 signalling pathway.